Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 15, 04 December 2023
Open
Access | Article
The extracellular matrix in peritoneal metastatic carcinoma
* Author to whom correspondence should be addressed.
Abstract
The peritoneum is a relatively common site for the metastasis of cancers that develop near the peritoneal cavity, such as gastric cancer, colorectal cancer (CRC), ovarian cancer, and low-grade appendiceal mucinous adenocarcinoma (LAMN). Peritoneal metastasis (PM) results from direct implantation and growth or microvascular metastasis of cancer cells to the peritoneum and is often associated with a poor prognosis. The biological features of peritoneal metastatic tumours are significantly altered, and the tumour microenvironment (TME) is profoundly abnormal. The extracellular matrix (ECM), a highly dynamic part of the TME, exhibits unique biological properties and influences tumour cells (TCs) behaviour and invasion. In this review, I focus on the hallmarks of cancer; the biology of CRC, PM from CRC, LAMN and pseudomyxoma peritonei (PMP, resulting from the intraperitoneal spread of LAMN); and the structural features of the cancer ECM and mucus and their roles in tumour growth, TCs invasion and drug resistance. The study of the ECM has led to a deeper understanding of peritoneal metastatic tumours and provides new insights for developing new biomarkers and targeted drugs.
Keywords
Extracellular matrix, Peritoneal metastasis, Colorectal cancer, Low-grade appendiceal mucinous neoplasm, Mucus
References
1. Xia, C., et al., Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chinese medical journal, 2022. 135(5): p. 584-590.
2. Karlsson, S. and H. Nyström, The extracellular matrix in colorectal cancer and its metastatic settling – Alterations and biological implications. Critical reviews in oncology/hematology, 2022. 175: p. 103712-103712.
3. Sung, H., et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2021.
4. Decellularized Normal and Tumor Extracellular Matrix as Scaffold for Cancer Organoid Cultures of Colorectal Peritoneal Metastases. Obesity, fitness, & wellness week, 2022: p. 901.
5. Cox, T.R., The matrix in cancer. Nature reviews. Cancer, 2021. 21(4): p. 217-238.
6. Hanahan, D. and R.A. Weinberg, The Hallmarks of Cancer. Cell, 2000. 100(1): p. 57-70.
7. Hanahan, D. and Robert A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell, 2011. 144(5): p. 646-674.
8. Hanahan, D., Hallmarks of Cancer: New Dimensions. Cancer discovery, 2022. 12(1): p. 31-46.
9. Thienpont, B., L. Van Dyck, and D. Lambrechts, Tumors smother their epigenome. Molecular & cellular oncology, 2016. 3(6): p. e1240549-e1240549.
10. Mohammadi, H. and E. Sahai, Mechanisms and impact of altered tumour mechanics. Nature cell biology, 2018. 20(7): p. 766-774.
11. Flavahan, W.A., E. Gaskell, and B.E. Bernstein, Epigenetic plasticity and the hallmarks of cancer. Science (American Association for the Advancement of Science), 2017. 357(6348).
12. He, R., et al., H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity. Oncogene, 2022. 41(21): p. 2958-2972.
13. Bi, M., et al., Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. Nature cell biology, 2020. 22(6): p. 701-715.
14. Finicle, B.T., V. Jayashankar, and A.L. Edinger, Nutrient scavenging in cancer. Nature reviews. Cancer, 2018. 18(10): p. 619-633.
15. Fais, S. and M. Overholtzer, Cell-in-cell phenomena in cancer. Nature reviews. Cancer, 2018. 18(12): p. 758-766.
16. Bartosh, T.J., et al., Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs). Proceedings of the National Academy of Sciences - PNAS, 2016. 113(42): p. E6447-E6456.
17. Fais, S. and M. Overholtzer, Cell-in-cell phenomena, cannibalism, and autophagy: is there a relationship? Cell death & disease, 2018. 9(2): p. 95-3.
18. Tonnessen-Murray, C.A., et al., Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival. The Journal of cell biology, 2019. 218(11): p. 3827-3844.
19. Black, J.R.M. and N. McGranahan, Genetic and non-genetic clonal diversity in cancer evolution. Nature reviews. Cancer, 2021. 21(6): p. 379-392.
20. Miles, L.A., et al., Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature (London), 2020. 587(7834): p. 477-482.
21. Erickson, A., et al., Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature (London), 2022. 608(7922): p. 360-3.
22. Gast, C.E., et al., Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science advances, 2018. 4(9): p. eaat7828-eaat7828.
23. Milo, I., et al., The immune system profoundly restricts intratumor genetic heterogeneity. Science immunology, 2018. 3(29): p. eaat1435.
24. Nejman, D., et al., The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science (American Association for the Advancement of Science), 2020. 368(6494): p. 973-980.
25. Cullin, N., et al., Microbiome and cancer. Cancer cell, 2021. 39(10): p. 1317-1341.
26. Fu, A., et al., Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell, 2022. 185(8): p. 1356-1372.e26.
27. Niño, J.L.G., et al., Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature (London), 2022. 611(7937): p. 810-4.
28. Paone, P. and P.D. Cani, Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut, 2020. 69(12): p. 2232-2243.
29. Tajima, Y., et al., Differential analysis of microbiomes in mucus and tissues obtained from colorectal cancer patients. Scientific reports, 2022. 12(1): p. 18193-18193.
30. Xia, L., et al., The cancer metabolic reprogramming and immune response. Molecular cancer, 2021. 20(1): p. 28-28.
31. Virtuoso, A., et al., Tumor Microenvironment and Immune Escape in the Time Course of Glioblastoma. Molecular neurobiology, 2022. 59(11): p. 6857-6873.
32. Vaupel, P. and G. Multhoff, Revisiting the Warburg effect: historical dogma versus current understanding. The Journal of physiology, 2021. 599(6): p. 1745-1757.
33. Hinshaw, D.C. and L.A. Shevde, The tumor microenvironment innately modulates cancer progression. Cancer research (Chicago, Ill.), 2019. 79(18): p. 4557-4566.
34. Chambers, A.M., et al., Adenosinergic Signaling Alters Natural Killer Cell Functional Responses. Frontiers in immunology, 2018. 9: p. 2533-2533.
35. Ma, X., et al., Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. Cell metabolism, 2019. 30(1): p. 143-156.e5.
36. Baumann, T., et al., Regulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal. Nature immunology, 2020. 21(5): p. 555-566.
37. Myer, P.A., et al., The Genomics of Colorectal Cancer in Populations with African and European Ancestry. Cancer discovery, 2022. 12(5): p. 1282-1293.
38. Siegel, R.L., et al., Colorectal cancer statistics, 2020. CA: a cancer journal for clinicians, 2020. 70(3): p. 145-164.
39. Al-Shamsi, H.O., et al., Molecular spectrum of KRAS , NRAS , BRAF , PIK3CA , TP53 , and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. Journal of gastrointestinal oncology, 2016. 7(6): p. 882-902.
40. Zhu, G., et al., Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular cancer, 2021. 20(1): p. 143-143.
41. Chen, Z., et al., Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway. Molecular medicine (Cambridge, Mass.), 2020. 26(1): p. 14-14.
42. Dienstmann, R. and J. Tabernero, Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. The cancer journal (Sudbury, Mass.), 2016. 22(3): p. 149-155.
43. Saller, J., et al., Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment. Clinical colorectal cancer, 2020. 19(2): p. 123-131.
44. Kawasaki, T., et al., CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Modern pathology, 2008. 21(3): p. 245-255.
45. Qin, J., et al., A human gut microbial gene catalogue established by metagenomic sequencing. Nature (London), 2010. 464(7285): p. 59-65.
46. Fang, Y., et al., The roles of microbial products in the development of colorectal cancer: a review. Bioengineered, 2021. 12(1): p. 720-735.
47. Perillo, F., et al., Gut Microbiota Manipulation as a Tool for Colorectal Cancer Management: Recent Advances in Its Use for Therapeutic Purposes. International journal of molecular sciences, 2020. 21(15): p. 5389.
48. Zhao, L., W.C. Cho, and M.R. Nicolls, Colorectal Cancer-Associated Microbiome Patterns and Signatures. Frontiers in genetics, 2021. 12: p. 787176-787176.
49. Cao, H., et al., Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis: Bile acid, dysbiosis and CRC. International journal of cancer, 2017. 140(11): p. 2545-2556.
50. Hwang, S., et al., Zerumbone Suppresses Enterotoxigenic Bacteroides fragilis Infection-Induced Colonic Inflammation through Inhibition of NF-κΒ. International journal of molecular sciences, 2019. 20(18): p. 4560.
51. Guo, P., et al., FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. Journal of experimental & clinical cancer research, 2020. 39(1): p. 1-202.
52. Colangelo, T., et al., Friend or foe?: The tumour microenvironment dilemma in colorectal cancer. Biochimica et biophysica acta. Reviews on cancer, 2017. 1867(1): p. 1-18.
53. Zhou, R.W., et al., A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nature communications, 2022. 13(1): p. 6041-6041.
54. Zhang, R., et al., Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. Cell death & disease, 2019. 10(4): p. 273-273.
55. Lu, Y., et al., MondoA–Thioredoxin-Interacting Protein Axis Maintains Regulatory T-Cell Identity and Function in Colorectal Cancer Microenvironment. Gastroenterology (New York, N.Y. 1943), 2021. 161(2): p. 575-591.e16.
56. Roth, L., et al., Peritoneal metastasis: Current status and treatment options. Cancers, 2022. 14(1): p. 60.
57. Klevansky, M., et al., The impact of primary tumour resection and sidedness in patients with synchronous metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC). Journal of clinical oncology, 2018. 36(4_suppl): p. 739-739.
58. Lund-Andersen, C., et al., Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: A narrative review. Journal of gastrointestinal oncology, 2021. 12(Suppl 1): p. S191-S203.
59. Kim, S.-C., et al., Establishment and Characterization of Paired Primary and Peritoneal Seeding Human Colorectal Cancer Cell Lines: Identification of Genes That Mediate Metastatic Potential. Translational oncology, 2018. 11(5): p. 1232-1243.
60. Gong, J., et al., Reprogramming of lipid metabolism in cancer-associated fibroblasts potentiates migration of colorectal cancer cells. Cell death & disease, 2020. 11(4): p. 267-267.
61. Lemoine, L., P. Sugarbaker, and K. Van Der Speeten, Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World journal of gastroenterology : WJG, 2016. 22(34): p. 7692-7707.
62. Raghavan, S., et al., Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. Journal for immunotherapy of cancer, 2019. 7(1): p. 190-190.
63. Demuytere, J., et al., The role of the peritoneal microenvironment in the pathogenesis of colorectal peritoneal carcinomatosis. Experimental and molecular pathology, 2020. 115: p. 104442-104442.
64. Li, P., et al., PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. The Journal of experimental medicine, 2010. 207(9): p. 1853-1862.
65. Nieman, K.M., et al., Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature medicine, 2011. 17(11): p. 1498-1503.
66. Hissong, E. and R.K. Yantiss, The Frontiers of Appendiceal Controversies: Mucinous Neoplasms and Pseudomyxoma Peritonei. The American journal of surgical pathology, 2022. 46(1): p. E27-E42.
67. Hegg, K.S., et al., Macroscopic and microscopic characteristics of low grade appendiceal mucinous neoplasms (LAMN) on appendectomy specimens and correlations with pseudomyxoma peritonei development risk. Annals of diagnostic pathology, 2020. 48: p. 151606-151606.
68. Yanai, Y., et al., Molecular and clinicopathological features of appendiceal mucinous neoplasms. Virchows Archiv : an international journal of pathology, 2021. 478(3): p. 413-426.
69. Yajima, N., et al., Immunohistochemical expressions of cytokeratins, mucin core proteins, p53, and neuroendocrine cell markers in epithelial neoplasm of appendix. Human pathology, 2005. 36(11): p. 1217-1225.
70. Alakus, H., et al., Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome medicine, 2014. 6(5): p. 43-43.
71. Nishikawa, G., et al., Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. British journal of cancer, 2013. 108(4): p. 951-958.
72. Dilly, A.K., et al., Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors. Translational research : the journal of laboratory and clinical medicine, 2016. 169: p. 19-30.e1.
73. Pillai, K., et al., A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei. International journal of cancer, 2014. 134(2): p. 478-486.
74. Pillai, K.M.S., et al., Mucolysis by Ascorbic Acid and Hydrogen Peroxide on Compact Mucin Secreted in Pseudomyxoma Peritonei. The Journal of surgical research, 2012. 174(2): p. e69-e73.
75. Liu, X., et al., Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clinical chemistry (Baltimore, Md.), 2014. 60(7): p. 1004-1011.
76. Saarinen, L., et al., Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei. PloS one, 2017. 12(4): p. e0174898-e0174898.
77. He, Y., et al., Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy? Frontiers in cell and developmental biology, 2021. 9: p. 739161-739161.
78. Yin, H., et al., Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness. Nature communications, 2021. 12(1): p. 4230-4230.
79. Sullivan, W.J., et al., Extracellular Matrix Remodeling Regulates Glucose Metabolism through TXNIP Destabilization. Cell, 2018. 175(1): p. 117-132.e21.
80. Henke, E., R. Nandigama, and S. Ergün, Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Frontiers in molecular biosciences, 2020. 6: p. 160-160.
81. Kumara, H.M.C.S., et al., Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases. World journal of gastrointestinal oncology, 2021. 13(8): p. 880-892.
82. Patwardhan, S., et al., ECM stiffness-tuned exosomes drive breast cancer motility through thrombospondin-1. Biomaterials, 2021. 279: p. 121185-121185.
83. Deligne, C. and K.S. Midwood, Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies? Frontiers in oncology, 2021. 11: p. 620773-620773.
84. Kuermanbayi, S., et al., In situ monitoring of functional activity of extracellular matrix stiffness-dependent multidrug resistance protein 1 using scanning electrochemical microscopy. Chemical science (Cambridge), 2022. 13(35): p. 10349-10360.
85. Lau, Eunice Yuen T., et al., Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. Cell reports (Cambridge), 2016. 15(6): p. 1175-1189.
86. Lim, S.B., et al., Addressing cellular heterogeneity in tumor and circulation for refined prognostication. Proceedings of the National Academy of Sciences - PNAS, 2019. 116(36): p. 17957-17962.
87. Pearce, O.M.T., et al., Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer discovery, 2018. 8(3): p. 304-319.
88. Herath, M., et al., The Role of the Gastrointestinal Mucus System in Intestinal Homeostasis: Implications for Neurological Disorders. Frontiers in cellular and infection microbiology, 2020. 10: p. 248-248.
89. Coleman, O.I. and D. Haller, Microbe–mucus interface in the pathogenesis of colorectal cancer. Cancers, 2021. 13(4): p. 1-18.
90. Belle, N.M., et al., TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. Nature communications, 2019. 10(1): p. 4408-13.
91. Morampudi, V., et al., The goblet cell-derived mediator RELM-β drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. Mucosal immunology, 2016. 9(5): p. 1218-1233.
92. Zeng, Y., et al., MUC1 predicts colorectal cancer metastasis: A systematic review and meta-analysis of case controlled studies. PloS one, 2015. 10(9): p. e0138049-e0138049.
93. De Arcangelis, A., et al., Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut, 2017. 66(10): p. 1748-1760.
94. Ribeirinho-Soares, S., et al., Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients. BMC cancer, 2021. 21(1): p. 359-359.
95. Lin, Y.-L. and Y. Li, The biological synthesis and the function of mucin 2 in pseudomyxoma peritonei. Cancer management and research, 2021. 13: p. 7909-7917.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-193-3
- ISBN (Online)
- 978-1-83558-194-0
- Published Date
- 04 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/15/20240464
- Copyright
- 04 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited